The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B

Yong Han Paik, Kwang Hyub Han, Sun Pyo Hong, Hyun Woong Lee, Kwan Sik Lee, Soo Ok Kim, Ji Eun Shin, Sang Hoon Ahn, Chae Yoon Chon, Young Myoung Moon

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The early emergence of lamivudine (3TC)-resistant tyrosine-methionine- aspartate-aspartate (YMDD) mutants has been reported during 3TC therapy in patients with chronic hepatitis B (CHB) in hepatitis B virus (HBV)-endemic areas; however, its clinical impact during long-term 3TC therapy is unknown. This study was performed to investigate the impact of the early emergence of YMDD mutants 3 months after the initiation of treatment on the outcomes of long-term 3TC therapy in HBV e antigen (HBeAg)-positive CHB. We analysed YMDD genotypes in consecutive samples from 30 patients with HBeAg positive CHB throughout 3TC treatment using both restriction fragment length polymorphism and mass spectrometric assays. Long-term outcome was compared between patients who had YMDD mutations detected at 3 months and those who had no mutations. YMDD mutation was detected in 16 (53.3%) out of 30 patients at 3 months and only the rtM204I mutation was found. Cumulative HBeAg loss rates at 3 years was 12.5% and 57.4% in patients who had the rtM204I mutant and wild-type virus at 3 months, respectively (P=0.010). Cumulative viral breakthrough rates at 3 years was 75.0% and 14.3% in patients who had the rtM204I mutant and wild-type virus at 3 months, respectively (P=0.002). Logistic regression revealed that YMDD mutation at 3 months was significantly related to viral breakthrough within 24 months (P=0.003). In conclusion, early detection for HBV YMDD mutation at 3 months may be useful to predict the long-term outcomes of 3TC therapy in patients with HBeAg-positive CHB in HBV-endemic areas.

Original languageEnglish
Pages (from-to)447-455
Number of pages9
JournalAntiviral Therapy
Volume11
Issue number4
Publication statusPublished - 2006 Jul 14

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B'. Together they form a unique fingerprint.

  • Cite this

    Paik, Y. H., Han, K. H., Hong, S. P., Lee, H. W., Lee, K. S., Kim, S. O., Shin, J. E., Ahn, S. H., Chon, C. Y., & Moon, Y. M. (2006). The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. Antiviral Therapy, 11(4), 447-455.